Business Context and Reporting Period
SeaStar Medical Holding Corp (ICU) filed a Form 8-K on July 3, 2024, reporting a potential violation of Nasdaq Listing Rule 5635(d)(2). The filing concerns the issuance of common stock upon the conversion of convertible notes and exercise of warrants issued to an institutional investor, which may have required additional shareholder approval.
Key Financial Metrics
The filing does not provide current revenue, profit, cash flow, or margin data. However, it details specific financing activities:
- Convertible Notes: Aggregate issuance of $9.8 million in four tranches under a Securities Purchase Agreement dated March 15, 2023.
- Warrants: Issuance of warrants equal to 25% of the conversion amount of the notes.
- Amendments:
- August 7, 2023: $2.2 million in additional notes; 4,765,620 additional warrants (190,624 post-split) at an exercise price of $0.20 ($5.00 post-split).
- December 11, 2023: $2.2 million in additional notes; 1,055,416 additional warrants (42,216 post-split).
- Conversion Price Adjustment: Conversion price of remaining notes from the first two tranches was reset to $0.20 ($5.00 post-split).
Material Changes
The primary material change is the notification to Nasdaq regarding a potential listing rule violation. The Company identified that the issuance of shares and the adjustment of the conversion price to $0.20 (below the initial floor price) may have occurred without the requisite shareholder approval. This contrasts with the initial approval granted at the 2023 Annual Meeting of Stockholders on June 28, 2023, which the Company believed covered the entire transaction.
Outlook, Risks, and Management Commentary
Management Action: The Company is requesting Nasdaq to determine if the specific issuances and price adjustments violated Listing Rule 5635(d)(2). The Company committed to fully comply with all Nasdaq shareholder approval requirements, engage advisers, and notify Nasdaq prior to issuing any securities for one year following the notice date.
Risks and Contingencies:
- Potential delisting or failure to satisfy continued listing standards if Nasdaq determines a violation occurred.
- Uncertainty regarding the validity of the share issuances and warrant exercises if shareholder approval is deemed retroactively required.
Unusual Items: The filing explicitly states it does not constitute an admission that the potential noncompliance is material.
Investor Verification Checklist
- Confirm Nasdaq's final determination regarding the violation of Listing Rule 5635(d)(2).
- Verify if the Company will be required to obtain retroactive shareholder approval for the $9.8 million note issuance and associated warrants.
- Monitor the Company's compliance with the one-year pre-issuance notification commitment to Nasdaq.
- Review the impact of the potential listing issue on the trading status of Common Stock (ICU) and Warrants (ICUCW) on The Nasdaq Stock Market.